| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-727 | |
| Phytochemical name or plant extracts | Cimigenol | |
| PMID | 30584366 | |
| Literature evidence | CONCLUSION: These results suggested that the selective compounds isolated from C. yunnanensis Hsiao could be the promising new agents for TNBC treatment. | |
| IUPAC name | (1S,2R,3S,4R,7R,9S,12R,14S,17R,18R,19R,21R,22S)-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosane-2,9-diol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid | |
| Source of phytochemicals or plant Extracts | Cimicifuga yunnanensis | |
| Geographical availability | China North-Central, China South-Central | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 0.1 µg/mL against MCF-7 0.32 µg/mL against MDA-MB-231 0.21 µg/mL against SKBR-3 | |
| Potency | Notably, we found that compounds 4 and 13 have promising antitumor effect on MDA-MB-231, a highly aggressive TNBC cell line. | |
| Cell line/ mice model | MCF-7, MDA-MB 231, SK-BR3 | |
| Additional information | These results suggested that the selective compounds isolated from C. yunnanensis Hsiao could be the promising new agents for TNBC treatment. | |
| PubChem ID | 16020000 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:709452-1 | |
| Safety | NA |